268 related articles for article (PubMed ID: 10026768)
1. Evaluation and management of the man who has failed primary curative therapy for prostate cancer.
Ornstein DK; Oh J; Herschman JD; Andriole GL
Urol Clin North Am; 1998 Nov; 25(4):591-601. PubMed ID: 10026768
[TBL] [Abstract][Full Text] [Related]
2. Evaluation and management of men whose radical prostatectomies failed: results of an international survey.
Ornstein DK; Colberg JW; Virgo KS; Chan D; Johnson ET; Oh J; Johnson FE
Urology; 1998 Dec; 52(6):1047-54. PubMed ID: 9836553
[TBL] [Abstract][Full Text] [Related]
3. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
Stephenson AJ; Shariat SF; Zelefsky MJ; Kattan MW; Butler EB; Teh BS; Klein EA; Kupelian PA; Roehrborn CG; Pistenmaa DA; Pacholke HD; Liauw SL; Katz MS; Leibel SA; Scardino PT; Slawin KM
JAMA; 2004 Mar; 291(11):1325-32. PubMed ID: 15026399
[TBL] [Abstract][Full Text] [Related]
4. HIFU as salvage first-line treatment for palpable, TRUS-evidenced, biopsy-proven locally recurrent prostate cancer after radical prostatectomy: a pilot study.
Asimakopoulos AD; Miano R; Virgili G; Vespasiani G; Finazzi Agrò E
Urol Oncol; 2012 Sep; 30(5):577-83. PubMed ID: 21292508
[TBL] [Abstract][Full Text] [Related]
5. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control.
Pound CR; Partin AW; Epstein JI; Walsh PC
Urol Clin North Am; 1997 May; 24(2):395-406. PubMed ID: 9126237
[TBL] [Abstract][Full Text] [Related]
7. Prostate specific antigen only progression of prostate cancer.
Moul JW
J Urol; 2000 Jun; 163(6):1632-42. PubMed ID: 10799151
[TBL] [Abstract][Full Text] [Related]
8. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
9. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
10. [Salvage radical prostatectomy].
Hautmann RE
Urologe A; 2006 Oct; 45(10):1260-5. PubMed ID: 16983529
[TBL] [Abstract][Full Text] [Related]
11. [Functional and oncological outcome of salvage prostatectomy of locally recurrent prostate cancer following radiation therapy].
Heidenreich A; Ohlmann C; Ozgür E; Engelmann U
Urologe A; 2006 Apr; 45(4):474-81. PubMed ID: 16465521
[TBL] [Abstract][Full Text] [Related]
12. Salvage radical prostatectomy for radiorecurrent prostate cancer: morbidity revisited.
Vaidya A; Soloway MS
J Urol; 2000 Dec; 164(6):1998-2001. PubMed ID: 11061900
[TBL] [Abstract][Full Text] [Related]
13. Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy.
Pisters LL; Leibovici D; Blute M; Zincke H; Sebo TJ; Slezak JM; Izawa J; Ward JF; Scott SM; Madsen L; Spiess PE; Leibovich BC
J Urol; 2009 Aug; 182(2):517-25; discussion 525-7. PubMed ID: 19524984
[TBL] [Abstract][Full Text] [Related]
14. Early salvage radiation therapy combined with short-term hormonal therapy in recurrent prostate cancer after radical prostatectomy: single-institution 4-year data on outcome, toxicity, health-related quality of life and co-morbidities from 184 consecutive patients treated with 70 Gy.
Cortés-González JR; Castellanos E; Sandberg K; Eriksson MH; Wiklund P; Carlsson S; Cohn-Cedermark G; Harmenberg U; Gustafsson O; Levitt SH; Lennernäs B; Brandberg Y; Márquez M; Kälkner KM; Nilsson S
Int J Oncol; 2013 Jan; 42(1):109-17. PubMed ID: 23151842
[TBL] [Abstract][Full Text] [Related]
15. Current status of local salvage therapies following radiation failure for prostate cancer.
Touma NJ; Izawa JI; Chin JL
J Urol; 2005 Feb; 173(2):373-9. PubMed ID: 15643174
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy.
Raj GV; Partin AW; Polascik TJ
Cancer; 2002 Feb; 94(4):987-96. PubMed ID: 11920467
[TBL] [Abstract][Full Text] [Related]
17. Hypofractionated radiotherapy as salvage for rising prostate-specific antigen after radical prostatectomy.
Lee LW; McBain CA; Swindell R; Wylie JP; Cowan RA; Logue JP
Clin Oncol (R Coll Radiol); 2004 Dec; 16(8):517-22. PubMed ID: 15630843
[TBL] [Abstract][Full Text] [Related]
18. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
19. Evaluation and management of prostate-specific antigen recurrence after radical prostatectomy for localized prostate cancer.
Naito S
Jpn J Clin Oncol; 2005 Jul; 35(7):365-74. PubMed ID: 15976063
[TBL] [Abstract][Full Text] [Related]
20. Prostate brachytherapy: treatment strategies.
Stone NN; Stock RG
J Urol; 1999 Aug; 162(2):421-6. PubMed ID: 10411050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
